Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate

Author： Sonmez Mehmet   Akagun Tulin   Cobanoglu Umit   Topbas Murat   Erkut Nergiz   Yilmaz Mustafa   Ovali Ercument   Omay Serdar Bedii  

Publisher： Maney Publishing

ISSN： 1024-5332

Source： Hematology, Vol.14, Iss.4, 2009-08, pp. : 220-223

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite

Bilateral Toxoplasma Retinochoroiditis in a Patient with Chronic Myeloid Leukemia Treated with Imatinib Mesylate

By Basu Soumyava   Das Taraprasad   Biswas Ghanshyam  

Ocular Immunology and Inflammation, Vol. 18, Iss. 1, 2010-01 ,pp. : 64-65

Informa Healthcare

Access to resources Recommend Favorite

The expression of LMO2 protein in acute B-cell and myeloid leukemia

By Cobanoglu Umit   Sonmez Mehmet   Ozbas Hasan Mucahit   Erkut Nergis   Can Gamze  

Hematology, Vol. 15, Iss. 3, 2010-06 ,pp. : 132-134

Maney Publishing

Access to resources Recommend Favorite

Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

By Carella Angelo   Lerma Enrica  

Annals of Hematology, Vol. 86, Iss. 10, 2007-10 ,pp. : 749-752

Springer Publishing Company

Access to resources Recommend Favorite

Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients

By  

Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders), Vol. 18, Iss. 3, 2018-12 ,pp. : 234-238

Bentham Science Publishers

Access to resources Recommend Favorite